- ZEN Graphene Solutions (ZEN) has developed a graphene-based virucidal ink which is 99 per cent effective against the COVID-19 virus
- The company has spent several months developing the ink for application to personal protective equipment (PPE)
- Under recent testing, the ink was still 99 per cent effective against COVID-19, 35 days after application to mask material
- The company has filed a provisional patent for the product, and is developing plans to fast-track its commercialisation
- ZEN Graphene Solutions (ZEN) is up 72.09 per cent and is currently trading for C$0.74 per share
ZEN Graphene Solutions (ZEN) has developed a graphene-based virucidal ink which is 99 per cent effective against the COVID-19 virus.
In April of this year, the company announced plans to create a graphene oxide-based ink to combat the coronavirus. Since then, ZEN Graphene has spent several months developing the ink for application to personal protective equipment (PPE).
The company conducted its most recent round of testing at a Biosafety Level 3 laboratory within Western University’s ImPaKT facility. During testing, two different concentrations of the ink were applied to the filtration material of a N95 mask.
The material was then exposed to the SARS-CoV-2 virus that causes COVID-19, and subsequently tested for antiviral properties. The results of this testing showed that both samples demonstrated significant and very encouraging virucidal activity.
The ink was 99 per cent effective in deactivating the virus, even 35 days after it was applied to the mask material.
ZEN Graphene’s CEO, Dr Francis Dube, commented on the game-changing results of the product testing.
“These recent results have dramatically exceeded our expectations, with our ink achieving 99 per cent virucidal activity against the SARS-CoV-2 virus 35 days after production of the samples.
“I am very proud of our Research and Development team for their exceptional work in developing this novel formulation.
“We are excited about the role our ink can play in the fight against this global pandemic, and are moving quickly to mobilise our resources to bring this product to market,” he said.
ZEN Graphene has already filed a provisional patent for its virucidal ink product. The company is now working to fast-track its commercialisation, pending regulatory approval.
ZEN Graphene Solutions (ZEN) is up 72.09 per cent and is trading at C$0.74 per share at 12:35pm EDT
